<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03249714</url>
  </required_header>
  <id_info>
    <org_study_id>COMB157G1301</org_study_id>
    <nct_id>NCT03249714</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label Ofatumumab</brief_title>
  <official_title>A 24-week, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Ofatumumab in Patients With Relapsing Multiple Sclerosis Followed by an Extended Treatment of at Least 24 Weeks With Open-label Ofatumumab</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study provided efficacy, safety, and pharmacokinetics (PK) data for patients with&#xD;
      relapsing multiple sclerosis (RMS) in Japan and the other countries&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study had 2 parts: A controlled Core and an open-label Extension.&#xD;
&#xD;
        -  Core part: A 24-week, randomized, double-blind, placebo controlled, parallel-group,&#xD;
           multicenter study evaluated the efficacy, safety and tolerability and PK of ofatumumab&#xD;
           in patients with RMS.&#xD;
&#xD;
        -  Extension part: The Core part was followed by an Extension part in which all patients&#xD;
           received open-label ofatumumab. In the Extension part, patients were treated for at&#xD;
           least 24 weeks and no longer than 48 weeks.&#xD;
&#xD;
      Sixty-four patients were randomized in a 2:1 ratio to ofatumumab or placebo in the Core part;&#xD;
      half of the study patients were from Japan and the other half from the other countries.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 15, 2018</start_date>
  <completion_date type="Actual">July 29, 2020</completion_date>
  <primary_completion_date type="Actual">December 26, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean number of gadolinium enhanced T1 lesions across 4 MRI scans (ofatumumab vs placebo)</measure>
    <time_frame>Week 12, 16, 20 and 24</time_frame>
    <description>The number of gadolinium enhanced T1 lesions on MRI scans will be measured by the central MRI reading center.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean number of gadolinium enhanced T1 lesions across 4 MRI scans (Japan vs other countries)</measure>
    <time_frame>Week 12, 16, 20 and 24, 36, 48 and end of study up to Week 72</time_frame>
    <description>The number of gadolinium enhanced T1 lesions on MRI scans will be measured by the central MRI reading center.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of new or enlarging T2 lesions on MRI scans compared to baseline</measure>
    <time_frame>Baseline, Week 12, 16, 20 and 24, 36, 48 and end of study up to Week 72</time_frame>
    <description>The number of new or enlarging T2 lesions on MRI scans compared to baseline will be measured by the central MRI reading center.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Annualized relapse rate</measure>
    <time_frame>Week 24, 48 and end of study up to Week 72</time_frame>
    <description>Annualized relapse rate is the number of confirmed relapses in a year calculated based on cumulative number of relapses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>B-cell count</measure>
    <time_frame>Baseline, Day 2, 5, 7, 14, Week 4, 12, 24, 28, 36, 48, 60 and 72</time_frame>
    <description>Blood samples will be collected at the scheduled visit. The CD19+ B-cell count will be measured by the central laboratory.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to first relapse</measure>
    <time_frame>Week 24, 48 and end of study up to Week 72</time_frame>
    <description>Time to first relapse is the period until the first relapse is confirmed from the first study drug injection.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">64</enrollment>
  <condition>Relapsing Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>OMB 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ofatumumab 20 mg subcutaneous injection on Days 1,7, 14 and every 4 weeks for 24 weeks in Core. Core placebo patients received loading dose at Weeks 25 and 26 and then all Extension patients received dose every 4 Weeks up to Week 48.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo-OMB 20 mg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo subcutaneous injection matching to ofatumumab every 4 weeks for 24 weeks in Core</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ofatumumab</intervention_name>
    <description>Provided in pre-filled syringes for subcutaneous injection (s.c.) administration containing 20 mg ofatumumab (50 mg/mL, 0.4 mL content)</description>
    <arm_group_label>OMB 20 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Matching placebo of ofatumumab</intervention_name>
    <description>Matching placebo in pre-filled syringes</description>
    <arm_group_label>Placebo-OMB 20 mg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of multiple sclerosis (MS)&#xD;
&#xD;
          -  Relapsing MS&#xD;
&#xD;
          -  At least 1 appearance of a new neurological abnormality or worsening of pre-existing&#xD;
             neurological abnormality during the previous 2 years prior to Screening AND an MRI&#xD;
             activity (Gd-enhanced T1 lesions or new or enlarging T2 lesions) in brain during the&#xD;
             previous 1 year prior to randomization&#xD;
&#xD;
          -  EDSS score of 0 to 5.5&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Primary progressive MS or SPMS without disease activity&#xD;
&#xD;
          -  Patients with an active chronic disease of the immune system other than MS&#xD;
&#xD;
          -  Patients at risk of developing or having reactivation of hepatitis&#xD;
&#xD;
          -  Patients with active systemic infections or with neurological findings consistent with&#xD;
             PML Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toon-city</city>
        <state>Ehime</state>
        <zip>791-0295</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Fukuoka city</city>
        <state>Fukuoka</state>
        <zip>812-8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sapporo city</city>
        <state>Hokkaido</state>
        <zip>063-0005</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Morioka</city>
        <state>Iwate</state>
        <zip>020-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sendai city</city>
        <state>Miyagi</state>
        <zip>980 8574</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sendai city</city>
        <state>Miyagi</state>
        <zip>983 8512</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kawagoe</city>
        <state>Saitama</state>
        <zip>350 8550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kodaira</city>
        <state>Tokyo</state>
        <zip>187-8551</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Shinjuku-ku</city>
        <state>Tokyo</state>
        <zip>160 8582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chiba</city>
        <zip>260 8677</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Niigata</city>
        <zip>951 8520</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Osaka</city>
        <zip>556-0016</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kazan</city>
        <zip>420021</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630007</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>August 11, 2017</study_first_submitted>
  <study_first_submitted_qc>August 11, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2017</study_first_posted>
  <last_update_submitted>May 19, 2021</last_update_submitted>
  <last_update_submitted_qc>May 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>double-blind</keyword>
  <keyword>placebo controlled</keyword>
  <keyword>ofatumumab</keyword>
  <keyword>relapsing multiple sclerosis</keyword>
  <keyword>Japanese patients</keyword>
  <keyword>MS</keyword>
  <keyword>RMS</keyword>
  <keyword>adult</keyword>
  <keyword>OMB157</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ofatumumab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.&#xD;
This trial data availability is according to the criteria and process described on https://www.clinicalstudydatarequest.com/.</ipd_description>
  </patient_data>
  <pending_results>
    <submitted>July 23, 2021</submitted>
    <returned>August 18, 2021</returned>
    <submitted>September 9, 2021</submitted>
    <returned>October 6, 2021</returned>
    <submitted>October 14, 2021</submitted>
    <returned>November 10, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

